Donald L. Reeves III, Senior Vice President of Outcomes at Itron, Inc. (NASDAQ:ITRI), executed a stock disposition on May 26, 2026. The transaction involved the sale of 319 shares of common stock, amounting to a total value of $26,912. This was accomplished through the sale of shares priced at $84.3667 per share.
The specific nature of this sale was tied to tax withholding obligations generated by the vesting of a restricted stock unit award. Following this disposal, Mr. Reeves III's direct ownership stake in Itron common stock stands at 29,100 shares.
This insider activity takes place against a backdrop of varied market performance and valuation metrics for Itron. As of recent trading data, the company trades around $85.30 per share, marking a decline of 26% over the past year's period. Despite this downward trend, some analyses suggest that the stock may be undervalued at current levels. Specifically, according to InvestingPro analysis, the stock carries a Price-to-Earnings (P/E) ratio of 13.6 relative to its projected near-term earnings growth potential.
More recently, Itron Inc. released financial results for the first quarter of 2026. The reported figures showed solid performance in key areas. The company achieved earnings per share (EPS) of $1.49, which surpassed the consensus analyst expectation of $1.23. Furthermore, Itron's revenue reached $587 million, exceeding the anticipated figure of $572.09 million.
However, despite these positive financial metrics, investor sentiment experienced some negative influence due to concerns regarding certain operational performance aspects, which contributed to a decrease in the stock's value.
The mixed signals are further emphasized by external analyst actions. Roth/MKM adjusted its price target for Itron from $150 down to $136 while maintaining an overall Buy rating. This downward revision of the price target was explicitly linked to a more subdued near-term revenue growth trajectory anticipated for the company. The firm cited complex projects and temporary regulatory issues as primary factors influencing this adjustment.
The confluence of these events paints a picture of conflicting signals regarding Itron's current financial health and future market outlook, encompassing both strong quarterly results and concerns over immediate growth rates. Investors are thus presented with diverse data points that require careful consideration when assessing the company's value proposition.
Risks
- Concerns over certain operational performance aspects negatively affected general investor sentiment despite strong quarterly figures.
- The adjustment by Roth/MKM of the price target suggests a more subdued near-term revenue growth trajectory, potentially due to complex projects or regulatory hurdles impacting market confidence.
More from Insider Trading